Here you will find the Funding Position of CCG Commissioned High-Cost Drugs within the Lancashire and South Cumbria Health Economy
A number of High-Cost Drugs, devices, procedures and products have been excluded from the scope of the national tariff of Payment by Results. These are listed on tab 13b of the following document:
2024/25 Annex A: The national tariff workbook
High-cost drugs are commissioned by:
The funding position of medicines directly commissioned by NHS England can be accessed via the NHS England website
Refer to the Manual for Prescribed Specialised Services for further information about prescribed specialised services, some of which are directly commissioned by NHS England and some by CCGs.
Date Posted: 01 - May - 2013
Approval Mechanism:
Hyperphosphataemia (NICE CG157)
Date Posted: 22 - Oct - 2024
Approval Mechanism: Blueteq
Date Posted: 05 - Mar - 2020
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 01 - Oct - 2019
Approval Mechanism: Prior approval blueteq form available
Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Date Posted: 05 - Mar - 2020
Approval Mechanism:
Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)
Date Posted: 05 - Mar - 2020
Approval Mechanism: Prior Approval Blueteq Form Available
Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)
Date Posted: 01 - Jul - 2015
Approval Mechanism: Prior Approval BLUETEQ form Available
Chronic spontaneous urticaria (NICE TA339)
Date Posted: 14 - Nov - 2022
Approval Mechanism:
Date Posted: 23 - Mar - 2020
Approval Mechanism:
Various indications - see Palliative Care Clinical Practice Summary Guidance
Date Posted: 01 - May - 2013
Approval Mechanism: N/A
Age-related macular degeneration (NICE TA155)
Date Posted: 01 - May - 2013
Approval Mechanism: Blueteq
Age-related macular degeneration (NICE TA155)
Date Posted: 01 - May - 2013
Approval Mechanism: Blueteq
Diabetic Macular Oedema (NICE TA274)
Date Posted: 16 - Oct - 2019
Approval Mechanism: Blueteq
Macular Oedema - retinal vein occlusion (NICE TA283)
Date Posted: 01 - Dec - 2013
Approval Mechanism: Blueteq
Choroidal neovascularisation (pathological myopia) NICE TA298
Date Posted: 01 - Sep - 2019
Approval Mechanism: Prior approval Blueteq form available
Date Posted: 14 - Sep - 2022
Approval Mechanism: Blueteq form
Date Posted: 22 - Oct - 2024
Approval Mechanism: Blueteq
Date Posted: 16 - Jun - 2023
Approval Mechanism:
Date Posted: 22 - Oct - 2024
Approval Mechanism: Blueteq
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval Blueteq Form Available
Rheumatoid arthritis (LSCMMG pathway)
